Participated · Series B · Jun 2026

Osanni Bio operates an innovation engine optimized for discovering scientific insights, designing novel drug concepts, and efficiently advancing programs to meaningful proof-of-concept. The platform-centric architecture combines centralized scientific and operational resources with an ecosystem of affiliate companies that receive graduated, de-risked programs and dedicated teams to scale them. Osanni is advancing multiple programs in ophthalmology and cardiology, among other areas. The company is headquartered in San Francisco and is led by a team of inventors and entrepreneurs with repeat company-creation experience. Financially, Osanni just closed a $190 million Series B led by Patient Square Capital to advance its pipeline and scale its discovery and development process.

Participated · Series C · Jan 2026

Beacon Therapeutics is a clinical-stage biotech focused on harnessing gene therapy for severe retinal disorders, notably X-linked retinitis pigmentosa (XLRP) and geographic atrophy. Its lead asset, laru-zova, is in pivotal trials and aims to become a best-in-class treatment for XLRP, with top-line data expected in the second half of 2026. The company estimates that about 14% of the 100,000 U.S. retinitis pigmentosa patients have the X-linked form, underscoring a significant unmet need. Newly raised capital will finance completion of laru-zova’s development and build the commercial infrastructure required for launch. Beacon is also advancing additional pipeline programs for geographic atrophy, an inherited cone-rod dystrophy, and another undisclosed ocular indication. Backed by a syndicate of leading life-science investors, the company remains pre-revenue and relies on venture funding to progress its portfolio.

Led · Series A · Feb 2025

Perceive Pharma is advancing novel small-molecule neuroprotective therapeutics with lead programs targeting glaucoma and other ophthalmic diseases. Its lead therapeutic candidate is PBI-671, drawn from a library of neuroprotective drug candidates assembled with a key industry partner. The company’s programs build on neuroprotective pathways first elucidated in a genomic screening by co-founders Drs. Don Zack and Derek Welsbie. Series A proceeds will fund development of first-in-class therapies to prevent vision loss in glaucoma and additional undisclosed disease areas. Perceive Pharma was spun out from Perceive Biotherapeutics, Inc. and is led by CEO K. Angela Macfarlane. Carol Gallagher, Pharm.D., has joined the board as an independent director.

Participated · Series A · Feb 2025

Perceive Pharma is advancing small-molecule neuroprotective therapeutics with lead pipeline programs in glaucoma and other ophthalmic diseases. The company’s lead candidate is PBI-671, and its Series A proceeds are intended to push the lead glaucoma program to clinical readiness. Perceive was spun out from Perceive Biotherapeutics and leverages genomic screening and retina-cell screening to identify neuroprotective pathways and drug candidates. The company is backed by a syndicate of life-science investors and is a resident of JLABS @ San Diego. Perceive emphasizes first-in-class approaches to prevent vision loss in patients who continue to progress despite current intraocular-pressure–lowering treatments. The team recently added industry veteran Dr. Carol Gallagher to its board to support development and corporate strategy. Perceive Biotherapeutics is developing a deep and diversified pipeline of ophthalmology therapeutics and technologies. Its lead programs target geographic atrophy/age-related macular degeneration (AMD) and glaucoma, with additional undisclosed disease areas in development. The company is a resident of JLABS @ San Diego, part of Johnson & Johnson Innovation’s incubator network, which provides access to lab space, equipment, and entrepreneurial resources. Led by CEO K. Angela Macfarlane and President Anne Rubin, Perceive plans to use new funding to accelerate its lead AMD program into the clinic and continue progress across its ophthalmology pipeline. The company closed a $78M Series B to support these development activities.

Participated · Series B · Sep 2022

SparingVision is a French biotech that develops genetic, innovative therapies in ophthalmology for the treatment of blinding inherited retinal diseases. Its lead programs are SPVN06 and SPVN20, which follow a mutation-agnostic approach aimed at treating retinitis pigmentosa (RP). The company intends to use new funding to advance these lead treatments, support first-in-human studies and bring lead assets to clinical validation. SparingVision has pursued a build-up strategy, including acquiring GAMUT Therapeutics and signing a strategic collaboration with Intellia Therapeutics. The company is led by Stéphane Boissel, President and Chief Executive Officer. The article references its first round of financing in 2020. SparingVision is focused on developing mutation-agnostic AAV gene therapies for ocular diseases, with a lead candidate targeting retinitis pigmentosa. Its lead candidate, SPVN06, combines a neurotrophic factor and an oxidative-stress–reducing enzyme in a single AAV construct intended to slow or stop photoreceptor degeneration across genetic forms of RP. The company notes there is currently no approved treatment for RP independent of genetic background and that RP affects nearly two million people worldwide. Proceeds from a €44.5 million financing will primarily fund GMP activities, including manufacture of a first clinical batch, IND/CTA regulatory work, and a planned first-in-man study scheduled to start in 2021. SparingVision is a spin-off of the Paris Vision Institute and plans to expand its management team and commence operations in the US. The press release also announced the appointment of Stéphane Boissel as Chief Executive Officer. SparingVision is a biotechnology company focused on discovery and development of innovative therapies for blinding inherited retinal diseases, particularly retinitis pigmentosa. Its lead program, SPVN06, is a gene-independent drug candidate intended to treat multiple genetic forms of the disease. The company is producing clinical batches and preparing to initiate first clinical trials in Europe and the United States in 2020. SparingVision completed the PHENOROD retrospective natural history study (NCT03975543) with results to be published, and plans the PHENOROD 2 prospective study to begin in Fall 2019. The company is a spin-off of the Paris Vision Institute and has received €15.5 million in prior investment from Bpifrance, the Foundation Fighting Blindness (US) and the Voir & Entendre Foundation. It recently secured €2.5 million in non-dilutive funding from the European EIC Accelerator to accelerate clinical and regulatory development while preparing for new fundraising.